Published in Blood on November 27, 2002
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Myeloproliferative disorders. Blood (2008) 3.37
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10
SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. J Am Coll Cardiol (2013) 1.43
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut (2007) 1.22
Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev (2013) 1.20
Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer (2003) 1.16
Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer (2010) 1.15
Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer (2004) 1.15
Developmental origins of adult disease. Pediatr Clin North Am (2009) 1.13
STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol (2010) 1.10
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Hot topics in epigenetic mechanisms of aging: 2011. Aging Cell (2012) 1.09
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Suppressors of cytokine signaling in health and disease. Pediatr Nephrol (2005) 1.02
HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer (2011) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) (2010) 0.98
Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis. World J Surg (2012) 0.94
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia (2010) 0.93
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation. Int J Oncol (2010) 0.93
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int (2014) 0.89
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling. J Cell Mol Med (2009) 0.88
Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol (2005) 0.88
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics (2007) 0.86
On the epigenetics of vascular regulation and disease. Clin Epigenetics (2012) 0.85
Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leuk Res (2008) 0.84
Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression. Oncotarget (2015) 0.83
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (2012) 0.83
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol (2014) 0.83
A SOCS-1 promoter variant is associated with total serum IgE levels. J Immunol (2011) 0.82
SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1. J Biol Chem (2008) 0.82
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. Cancers (Basel) (2014) 0.81
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs (2012) 0.81
Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells. Oncol Lett (2014) 0.80
Diabetic and metabolic programming: mechanisms altering the intrauterine milieu. ISRN Pediatr (2012) 0.78
Expression of SOCS-1 in the liver tissues of chronic hepatitis B and its clinical significance. World J Gastroenterol (2008) 0.78
Silencing of the SOCS-1 gene by CpG methylation? Blood (2003) 0.77
Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget (2015) 0.76
Physiological and pathological implications of 5-hydroxymethylcytosine in diseases. Oncotarget (2016) 0.75
Association of SOCS1 (- 820) (rs33977706) gene polymorphism with chronic periodontitis: A case-control study in Brazilians. Meta Gene (2015) 0.75
STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells. Am J Transl Res (2015) 0.75
Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget (2016) 0.75
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS One (2017) 0.75
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment. PLoS One (2017) 0.75
Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission. Exp Ther Med (2017) 0.75
Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia. Blood Cancer J (2017) 0.75
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
DNA methylation and cancer. Adv Genet (2010) 3.50
Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74
The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72
Notch signaling is essential for ventricular chamber development. Dev Cell (2007) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41
Allele-specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J (2002) 2.40
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics (2009) 2.21
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci (2007) 2.17
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle (2007) 2.12
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene (2005) 1.98
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet (2003) 1.93
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res (2004) 1.92
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem (2004) 1.82
Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques (2008) 1.81
Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res (2012) 1.80
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett (2010) 1.79
The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev (2005) 1.79
Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis (2003) 1.78
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res (2007) 1.77
E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific gene transcription. EMBO J (2005) 1.76
Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol (2012) 1.73